GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (NAS:AKTX) » Definitions » Cyclically Adjusted Price-to-FCF

AKTX (Akari Therapeutics) Cyclically Adjusted Price-to-FCF : (As of Jul. 10, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Akari Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Akari Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Akari Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Cyclically Adjusted Price-to-FCF Chart

Akari Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Akari Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Akari Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akari Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Akari Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Akari Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Akari Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.079/134.9266*134.9266
=-0.079

Current CPI (Mar. 2025) = 134.9266.

Akari Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -5.507 99.621 -7.459
201506 -1.934 100.684 -2.592
201509 11.486 100.392 15.437
201512 -11.455 99.792 -15.488
201603 -12.705 100.470 -17.062
201606 -9.672 101.688 -12.833
201609 -8.487 101.861 -11.242
201612 -11.037 101.863 -14.620
201703 -15.576 102.862 -20.431
201706 -8.031 103.349 -10.485
201709 -15.643 104.136 -20.268
201712 -11.699 104.011 -15.176
201803 -5.764 105.290 -7.386
201806 -10.857 106.317 -13.779
201809 -6.978 106.507 -8.840
201812 -6.019 105.998 -7.662
201903 0.290 107.251 0.365
201906 -5.937 108.070 -7.412
201909 -4.980 108.329 -6.203
201912 -3.207 108.420 -3.991
202003 -6.153 108.902 -7.623
202006 -2.847 108.767 -3.532
202009 -0.416 109.815 -0.511
202012 -3.221 109.897 -3.955
202103 -3.856 111.754 -4.656
202106 -2.529 114.631 -2.977
202109 -0.671 115.734 -0.782
202112 -2.101 117.630 -2.410
202203 -1.885 121.301 -2.097
202206 -2.890 125.017 -3.119
202212 0.000 125.222 0.000
202303 -1.289 127.348 -1.366
202306 -0.928 128.729 -0.973
202309 -0.484 129.860 -0.503
202312 -1.002 129.419 -1.045
202403 -0.601 131.776 -0.615
202406 -0.520 132.554 -0.529
202409 -0.122 133.029 -0.124
202412 -0.080 133.157 -0.081
202503 -0.079 134.927 -0.079

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Akari Therapeutics  (NAS:AKTX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Akari Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Akari Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
22 Boston Wharf Road, 7th Floor, Boston, MA, USA, 02210
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Executives
Donald Allen Williams director C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
David Byrne director C/O AKARI THERAPEUTICS, PLC, 24 WEST 40TH STREET, 8TH FLOOR, NEW YORK NY 10018
Robert M Shaw officer: General Counsel and Secretary C/O BIOTECHNOLOGY GENERAL CORP, ONE TOWER CENTER BLVD 14TH FLR, EAST BRUNSWICK NJ 08816
Clive Richardson director, officer: COO C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Rpc Pharma Ltd 10 percent owner C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Ray Prudo director, 10 percent owner C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Stuart Ungar director, 10 percent owner C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
James Hill director, 10 percent owner C/O LANDMARK FIDUCIAIRE (SUISSE) SA, 6 PLACE DES EAUX-VIVES, PO BOX 3461, GENEVA V8 1211
Mark S Cohen director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Gur Roshwalb director, officer: Chief Executive Officer C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Amos Eiran director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Lau Johnson Yiu Nam director